Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00321646
Recruitment Status : Completed
First Posted : May 4, 2006
Results First Posted : December 25, 2013
Last Update Posted : May 16, 2016
Beth Israel Deaconess Medical Center
Duke University
Genentech, Inc.
Information provided by (Responsible Party):
Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute

Brief Summary:
The main purpose of this trial is to collect information and to evaluate the effects, good or bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate cancer that are undergoing radical prostatectomy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Adenocarcinoma of the Prostate Drug: Bevacizumab Drug: Docetaxel Phase 2

Detailed Description:
  • Patients who are eligible for this study will undergo an endorectal MRI scan test before beginning the research study.
  • After the MRI, the patient will begin the docetaxel plus bevacizumab part of the study. Each treatment cycle starts on the day you receive both drugs and lasts 21 days. Patients will undergo a total of 6 cycles-5 with docetaxel plus bevacizumab and one with docetaxel alone.
  • At the beginning of each cycle, the patient will come into the clinic for a visit that will last about 3 hours. The following will happen at these visits: physical examination including vital signs and rectal exam; questions about the patients health and the medications they are taking; blood tests (both routine and research blood tests); urine tests; bevacizumab infusion; docetaxel infusion.
  • The patients first dose of bevacizumab will be given on Day 1 of the first cycle over 90 minutes. If the patient tolerates the 90-minute infusion well, later doses may be given over a shorter period of time.
  • The day before and the morning of the beginning of each cycle, the patient will be given a steroid called dexamethasone in pill form to help decrease the side effects of the treatment.
  • The above tests and procedures will be repeated every 21 days a total of five times. For the sixth time, the patient will have all the same tests and procedures except they will not receive bevacizumab.
  • After the six cycles, the patient will undergo another endorectal MRI.
  • One to two months after finishing the sixth cycle, the patient will undergo a radical prostatectomy to remove their prostate.
  • Two to three months after the surgery the patient will return to the clinic to have the following tests and procedures: questions about the patient's health; routine blood tests and research blood tests.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
Study Start Date : June 2006
Actual Primary Completion Date : November 2008
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: chemotherapy
docetaxel and bevacizumab prior to prostatectomy
Drug: Bevacizumab
Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
Other Name: Avastin

Drug: Docetaxel
Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
Other Name: Taxotere

Primary Outcome Measures :
  1. Endorectal MRI Response After Completion of 6 Cycles of Neoadjuvant Therapy [ Time Frame: after 6 months of neoadjuvant chemotherapy. ]
    A response was defined as a decrease in tumor size of >50% for the largest lesion in the prostate by endorectal MRI.

Secondary Outcome Measures :
  1. PSA Response After Completing 6 Cycles of Neoadjuvant Chemotherapy. [ Time Frame: after 6 months of ajuvant chemotherapy. ]
    The rate of PSA decline by 50% compared to baseline PSA.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological documentation of adenocarcinoma of the prostate, with available biopsy pathology. Material from this biopsy must be available for central review at DF/HCC by the beginning of the second cycle of therapy.
  • Potential candidate for radical prostatectomy
  • Must meet one or more of the below characteristics: Gleason score of 8, 9 or 10; serum PSA of greater than or equal to 20 ng/mL; clinical T stage of T3; PSA velocity of greater than or equal to 2ng/mL/year in the year prior to diagnosis; Gleason score of 7 and erMRI T3 disease; Greater than or equal to 50% of the total number of biopsy cores positive for prostate cancer and either PSA > 10ng/mL or Gleason score of 7 or clinical T stage of T2a, T2b or T2c.
  • Greater than six weeks since any major surgery
  • Serum testosterone > 100ng/dL
  • ECOG Performance Status of 0 or 1
  • ANC > 1,500/ul
  • Platelets > 100,000/ul
  • Total bilirubin, alkaline phosphatase, AST and ALT within normal limits
  • Creatinine < 2.0 x upper limit of normal

Exclusion Criteria:

  • History of prior radiation, surgery or hormonal therapy treatment for prostate cancer
  • Clinical evidence of metastatic prostate cancer
  • Ongoing oral steroid use
  • Pre-existing neuropathy of grade 2 or greater
  • Severe claustrophobia, inability to lie still in a magnet for 60 minutes, a pacemaker, or any other condition that would preclude proximity to a strong magnet.
  • History of the following conditions: unstable angina; symptomatic, clinically significant peripheral vascular disease; NY Heart Association Grade 2 or greater heart failure; uncontrolled hypertension; myocardial infarction or stroke < 12 months prior to enrollment; uncontrolled hypertension; active, uncontrolled infection; history of DVT, PE or known coagulopathy or bleeding diathesis; ongoing us of anticoagulant therapy; history of abdominal fistulas, GI perforation, or intra-abdominal abscess within 6 months prior to study entry; non-healing ulcer or fracture; history of another malignancy diagnosed within the last five years; spot urine protein: creatinine ratio > 1.0 at screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00321646

United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Mary-Ellen Taplin, MD
Beth Israel Deaconess Medical Center
Duke University
Genentech, Inc.
Principal Investigator: Mary-Ellen Taplin, MD Dana-Farber Cancer Institute

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mary-Ellen Taplin, MD, Assistant Professor of Medicine, HMS, Dana-Farber Cancer Institute Identifier: NCT00321646     History of Changes
Other Study ID Numbers: 05-438
First Posted: May 4, 2006    Key Record Dates
Results First Posted: December 25, 2013
Last Update Posted: May 16, 2016
Last Verified: April 2016

Keywords provided by Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute:
prostate cancer
radical prostatectomy

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action